...
机译:肾移植患者HCV治疗Peginterferon和利巴韦林:长期随访
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
Renal Unit Department of Medicine and Geriatrics Kwong Wah Hospital;
HCV; Treatment; Peginterferon; Renal transplant; Ribavirin;
机译:肾移植患者HCV治疗Peginterferon和利巴韦林:长期随访
机译:达格拉他韦/聚乙二醇干扰素lambda-1a /利巴韦林用于慢性HCV感染和血友病的患者,他们是初次或先前复发于聚乙二醇干扰素α-2a/利巴韦林的患者
机译:在治疗第8周时未检测到HCV-RNA导致在接受HCV G1治疗的晚期肝病患者中高度持续的病毒学应答:国际意大利/西班牙Boceprevir / Peginterferon / Ribavirin姓名患者计划
机译:HCV / HIV的患者在用Peginterferon Alfa-2a(Pegasys)加上利巴韦林(Copegegs)后HCV治疗后实现持续的病毒学反应,具有改善的健康相关的生活质量
机译:透析,肾脏移植和胰腺移植对糖尿病和肾衰竭患者的长期疗效:一项决策分析。
机译:在治疗结束后第24周持续的病毒学应答是用聚乙二醇干扰素加利巴韦林治疗的HCV NS3 / 4A蛋白酶抑制剂治疗的真实HCV感染患者中治疗结果的更好预测指标
机译:在治疗第8周时未检测到HCV-RNA会在经历过HCV G1治疗的晚期肝病患者中导致高度持续的病毒学应答:国际意大利/西班牙Boceprevir / Peginterferon /利巴韦林命名患者计划
机译:非裔美国人和其他未代表群体中的肾移植:患者选择治疗方式在终末期肾病中的作用。执行摘要和最终报告